New Research Study Provides Further Evidence of Strong Correlation of TriPath Imaging's ProEx C Biomarkers with Biopsy Evidence

Dow Jones

38 711,29

0,36%

Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.

S'inscrire

New Research Study Provides Further Evidence of Strong Correlation of TriPath Imaging's ProEx C Biomarkers with Biopsy Evidence

In-house and External Retrospective Research Studies Incorporating ProEx C Biomarkers Presented at 53rd Annual Scientific Meeting of the American Society of Cytopathology BURLINGTON, N.C., Nov. 7 /PRNewswire-FirstCall/ -- TriPath Imaging, Inc. (NASDAQ:TPTH) today announced that the results of a new in-house retrospective research study demonstrated that testing of cervical cytology specimens with Research Use Only (RUO) reagents incorporating the Company's proprietary ProEx C biomarkers yielded a 93% (p

Tripath Imaging (NASDAQ:TPTH)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024